• DOI:10.1101/2020.07.31.20161216
Corpus ID: 221089937

Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial

@article{Zhang2020ImmunogenicityAS,
  title={Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial},
  author={Y. Zhang and G. Zeng and H-X Pan and C. Li and B. Kan and Y-L Hu and H. Y. Mao and Q.-Q. Xin and K. Chu and W.-X. Han and Z. Chen and R. Tang and W.-D. Yin and X. Chen and X. Gong and C. Qin and Y.-S. Hu and X-Y Liu and G.-L. Cui and C. Jiang and H-m Zhang and J. Li and M. Yang and X.-J. Lian and Y. Song and J. Lu and X. Wang and M. Xu and Q. Gao and F. Zhu},
  journal={medRxiv},
  year={2020}
}

Y. Zhang, G. Zeng, +27 authors F. Zhu

Published 2020

Medicine

medRxiv

BACKGROUND The top priority for the control of COVID-19 pandemic currently is the development of a vaccine. A phase 2 trial conducted to further evaluate the immunogenicity and safety of a SARS-CoV-2 inactivated vaccine (CoronaVac). METHODS We conducted a randomized, double-blind, placebo-controlled trial to evaluate the optimal dose, immunogenicity and safety of the CoronaVac. A total of 600 healthy adults aged 18-59 years were randomly assigned to receive 2 injections of the trial vaccine at… CONTINUE READING

View via Publisher

medrxiv.org

Save to Library

Create Alert

Cite

Launch Research Feed